NCT01932385View on ClinicalTrials.gov

Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

August 1, 2013

Primary Completion Date

January 30, 2016

Study Completion Date

July 30, 2016

Conditions
Liver Cancer
Interventions
DRUG

Sorafenib

OTHER

Best Supportive Care

Trial Locations (1)

266042

Qingdao Central Hospital, Qingdao Cancer Hospital, Qingdao

All Listed Sponsors
lead

Qingdao Central Hospital

OTHER

NCT01932385 - Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter